Beware of thromboembolic risk in obese patients on direct oral anticoagulants (DOACs).
作者信息
Chattopadhyay Indrajit, Adhiyaman Vedamurthy, Ghiya Suhani
机构信息
Glan Clwyd Hospital, Rhyl, UK.
出版信息
Clin Med (Lond). 2018 Jun;18(3):267. doi: 10.7861/clinmedicine.18-3-267.
Abstract
摘要
相似文献
1
Beware of thromboembolic risk in obese patients on direct oral anticoagulants (DOACs).
Clin Med (Lond). 2018 Jun;18(3):267. doi: 10.7861/clinmedicine.18-3-267.
2
Lesson of the month 2: Pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine.
Clin Med (Lond). 2018 Feb;18(1):103-105. doi: 10.7861/clinmedicine.18-1-103.
3
Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients.
Hosp Pract (1995). 2019 Oct;47(4):181-185. doi: 10.1080/21548331.2019.1674586. Epub 2019 Nov 5.
4
Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland.
Br J Clin Pharmacol. 2019 Feb;85(2):422-431. doi: 10.1111/bcp.13814. Epub 2018 Dec 18.
5
Anticoagulation and BMI: effect of high body weight on the safety and efficacy of direct oral anticoagulants.
Future Cardiol. 2022 Sep;18(10):829-837. doi: 10.2217/fca-2021-0146. Epub 2022 Sep 2.
6
Body Mass Index Influence on the Clinical Outcomes for Nonvalvular Atrial Fibrillation Patients Admitted to a Hospital Treated with Direct Oral Anticoagulants: A Retrospective Cohort Study.
Drug Des Devel Ther. 2021 May 6;15:1931-1943. doi: 10.2147/DDDT.S303219. eCollection 2021.
7
Thromboembolic Events While Taking Direct Oral Anticoagulants: An Analysis of Post-market WHO Database Reports from 2012 to 2020.
Clin Drug Investig. 2022 Jul;42(7):593-598. doi: 10.1007/s40261-022-01165-3. Epub 2022 Jun 8.
8
Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real-world analysis.
Pacing Clin Electrophysiol. 2023 Jan;46(1):50-58. doi: 10.1111/pace.14623. Epub 2022 Dec 1.
9
Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study.
Circulation. 2023 Mar 7;147(10):782-794. doi: 10.1161/CIRCULATIONAHA.122.060687. Epub 2023 Feb 10.
10
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
Ann Pharmacother. 2016 Jun;50(6):486-501. doi: 10.1177/1060028016632785. Epub 2016 Feb 25.
本文引用的文献
1
Lesson of the month 2: Pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine.
Clin Med (Lond). 2018 Feb;18(1):103-105. doi: 10.7861/clinmedicine.18-1-103.
2
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.
J Thromb Haemost. 2016 Jun;14(6):1308-13. doi: 10.1111/jth.13323. Epub 2016 Apr 27.
3
A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?
Anatol J Cardiol. 2015;15(12):1020-9. doi: 10.5152/AnatolJCardiol.2015.6532.
4
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.
Br J Clin Pharmacol. 2013 Dec;76(6):908-16. doi: 10.1111/bcp.12114.
Zotero 插件